This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (109)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Cognitive Disorders  • Alert me on articles by topic

Michael S. Mega, MD, PhD; Donna M. Masterman, MD; Susan M. O'Connor, RNC; Terry R. Barclay, BA; Jeffrey L. Cummings, MD

Arch Neurol. 1999;56:1388-1393.

Background  Behavioral abnormalities are common in Alzheimer disease (AD); cholinergic treatment reduces the behavioral disturbances of some patients with AD. Characterizing the pretreatment profile of patients who are likely to respond to cholinergic therapy will aid the efficient use of clinical resources.

Objective  To determine the baseline behavioral profile for 86 patients with AD treated with the cholinesterase inhibitor donepezil hydrochloride.

Methods  Open-label retrospective study of treatment-related behavioral assessments. Based on previous double-blind placebo-controlled experience using the Neuropsychiatric Inventory (NPI), patients were divided into responder (4-point total NPI score decrease, indicating improvement), unchanged (±3-point total NPI score change), or nonresponder (4-point total NPI score increase, indicating worsening) groups. The Mini-Mental State Examination assessed cognitive response.

Results  Behavioral improvement was seen in 35 patients (41%), worsening in 24 (28%), and no change in 27 (31%). Comparison of profiles in behavioral responders vs nonresponders revealed significantly worse delusions (P=.04), agitation (P=.04), depression (P=.006), anxiety (P=.02), apathy (P=.003), disinhibition (P=.02), and irritability (P<.001) at baseline in responders. Five behaviors changed significantly from baseline, improving for the responders and worsening for the nonresponders: delusions (P=.003 for nonresponders, P=.004 for responders), agitation (P=.01), anxiety (P=.006 for nonresponders, P=.004 for responders), disinhibition (P=.02 for nonresponders, P=.05 for responders), and irritability (P=.003 for nonresponders, P=.001 for responders). The behavioral changes were dose dependent. Cognition did not change significantly with donepezil treatment within any group.

Conclusions  Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment.

From the Laboratory of Neuro Imaging (Dr Mega) and Alzheimer's Disease Research Center (Drs Mega, Masterman, and Cummings, Ms O'Connor, and Mr Barclay), Department of Neurology, and the Department of Psychiatry and Biobehavioral Sciences (Dr Cummings), University of California, Los Angeles, School of Medicine.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(11):1421-1422.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Three-Country Randomized Controlled Trial of a Psychosocial Intervention for Caregivers Combined With Pharmacological Treatment for Patients With Alzheimer Disease: Effects on Caregiver Depression
Mittelman et al.
AJGP 2008;16:893-904.
ABSTRACT | FULL TEXT  

Apathy Associated with Alzheimer Disease: Use of Dextroamphetamine Challenge
Lanctot et al.
AJGP 2008;16:551-557.
ABSTRACT | FULL TEXT  

Cholinesterase inhibitors in dementia: yes, no, or maybe?
Lemstra et al.
Age Ageing 2007;36:625-627.
FULL TEXT  

A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease
Lanctot et al.
AJGP 2007;15:888-898.
ABSTRACT | FULL TEXT  

Sensory Gating in Patients With Alzheimer's Disease and Their Biological Children
Ally et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2007;21:439-447.
ABSTRACT  

Clock Drawing and Frontal Lobe Behavioral Effects of Memantine in Alzheimer's Disease: A Rater-Blinded Study
Paskavitz et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2007;21:454-459.
ABSTRACT  

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings et al.
Neurology 2006;67:57-63.
ABSTRACT | FULL TEXT  

Symptoms Underlying Unawareness of Memory Impairment in Patients With Mild Alzheimer's Disease
Kazui et al.
J Geriatr Psychiatry Neurol 2006;19:3-12.
ABSTRACT  

Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics
Peters et al.
Neurology 2006;66:523-528.
ABSTRACT | FULL TEXT  

Prevalence of Apathy, Dysphoria, and Depression in Relation to Dementia Severity in Alzheimer's Disease
Landes et al.
J. Neuropsychiatry Clin. Neurosi. 2005;17:342-349.
ABSTRACT | FULL TEXT  

Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy: A Fludeoxyglucose F 18 Positron Emission Tomographic Study
Mega et al.
Arch Neurol 2005;62:721-728.
ABSTRACT | FULL TEXT  

Apathy: Why Care?
van Reekum et al.
J. Neuropsychiatry Clin. Neurosi. 2005;17:7-19.
ABSTRACT | FULL TEXT  

Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease
Lyketsos et al.
AJGP 2004;12:473-482.
ABSTRACT | FULL TEXT  

Management of Alzheimer's Disease
Grossberg and Desai
J. Gerontol. A Biol. Sci. Med. Sci. 2003;58:M331-353.
FULL TEXT  

Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis
Trinh et al.
JAMA 2003;289:210-216.
ABSTRACT | FULL TEXT  

Verification of Scale Sub-Domains in Elderly Patients With Dementia: A Confirmatory Factor-Analytic Approach
Kastango et al.
AJGP 2002;10:706-714.
ABSTRACT | FULL TEXT  

Alzheimer Disease
Cummings and Cole
JAMA 2002;287:2335-2338.
FULL TEXT  

Clinical Presentation of the ""Depression-Executive Dysfunction Syndrome"" of Late Life
Alexopoulos et al.
AJGP 2002;10:98-106.
ABSTRACT | FULL TEXT  

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
Feldman et al.
Neurology 2001;57:613-620.
ABSTRACT | FULL TEXT  

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad et al.
Neurology 2001;57:489-495.
ABSTRACT | FULL TEXT  

Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales
Perrault et al.
J Geriatr Psychiatry Neurol 2000;13:181-196.
ABSTRACT  

A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot et al.
Neurology 2000;54:2269-2276.
ABSTRACT | FULL TEXT  

Behavioral Responses to Cholinergic Therapy by Alzheimer's Patients
JWatch Psychiatry 2000;2000:13-13.
FULL TEXT